Merck & Co. Stock Drops Amid Positive Tulisokibart Data
Merck & Co.'s stock price is down by 0.45 percent in after-hours trading on October 2, 2026, at EUR 127.25. This change comes compared to its prior close of EUR 127.83 on October 1, 2026.
The company announced positive Phase 2b data for its treatment tulisokibart in a release dated September 30, 2026. The study met its primary endpoint, with 72 percent of patients in the high-dose group and 64 percent in the medium-dose group achieving HiSCR50, compared to 35 percent for placebo.
Merk plans to advance tulisokibart into Phase 3 development for the condition of hidradenitis suppurativa. The company will hold its third-quarter 2026 sales and earnings conference call on October 29, 2026, at 9:00 a.m. ET, during which executives will provide an overview of the quarter.